Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Serina Therapeutics Inc (SER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SER (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.81% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.53M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 3.81 - 8.05 | Updated Date 10/17/2025 |
52 Weeks Range 3.81 - 8.05 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4280.77% |
Management Effectiveness
Return on Assets (TTM) -132.37% | Return on Equity (TTM) -485.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 54404200 | Price to Sales(TTM) 396.36 |
Enterprise Value 54404200 | Price to Sales(TTM) 396.36 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 37.36 | Shares Outstanding 10537181 | Shares Floating 3271578 |
Shares Outstanding 10537181 | Shares Floating 3271578 | ||
Percent Insiders 47.87 | Percent Institutions 3.92 |
Upturn AI SWOT
Serina Therapeutics Inc
Company Overview
History and Background
Serina Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics utilizing its proprietary POZ Platform technology to address unmet medical needs in oncology, pain, and other areas. Founded to develop and commercialize POZ-modified therapeutics.
Core Business Areas
- Oncology: Development of POZ-modified therapeutics for the treatment of various cancers, including solid tumors and hematological malignancies. Focus is on improving drug delivery and efficacy while reducing side effects.
- Pain Management: Development of POZ-modified therapeutics for the treatment of chronic and acute pain conditions. Aim is to develop non-opioid pain management solutions with improved efficacy and safety profiles.
- Neurology: Exploration of POZ Platform in neurological disorder such as Parkinson's disease and multiple sclerosis.
Leadership and Structure
The company has a management team with expertise in drug development, clinical research, and commercialization. Specific leadership details and organizational structure are available on the company's website and SEC filings.
Top Products and Market Share
Key Offerings
- ST-2462: A POZ-modified topoisomerase II inhibitor in Phase 1/2 clinical trials for solid tumors. Market share data is not yet available due to its early stage of development. Competitors include companies developing other topoisomerase II inhibitors.
- ST-2464: A POZ-modified formulation for pain management. Preclinical development. Market share data is not yet available. Potential competitors are manufacturers of other pain medications (opioid and non-opioid) such as Pfizer, Teva.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The market is driven by an aging population, increasing prevalence of chronic diseases, and growing demand for innovative therapies.
Positioning
Serina Therapeutics is positioned as a company developing novel therapeutics based on its POZ platform. Its competitive advantage lies in its proprietary technology, which aims to improve drug delivery and efficacy while reducing toxicity.
Total Addressable Market (TAM)
The TAM for oncology and pain management therapeutics is estimated to be in the billions of dollars. Serina Therapeutics is targeting specific sub-segments within these markets, aiming to capture a portion of the TAM through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary POZ Platform technology
- Focus on unmet medical needs
- Experienced management team
- Pipeline of novel therapeutic candidates
Weaknesses
- Early stage of development
- Limited financial resources
- Dependence on key personnel
- No products currently on the market
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the POZ Platform to new therapeutic areas
- Successful clinical trials and regulatory approvals
- Growing demand for innovative therapies
Threats
- Competition from established pharmaceutical companies
- Failure to obtain regulatory approvals
- Clinical trial failures
- Patent disputes
- Economic downturn
Competitors and Market Share
Key Competitors
- PFE
- MRK
- BMY
Competitive Landscape
Serina Therapeutics faces intense competition from larger, more established pharmaceutical companies with greater financial resources and broader pipelines. Its advantage lies in its innovative POZ Platform technology, but it must successfully navigate the regulatory and commercialization challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited to the expansion of its pipeline and advancements in its POZ Platform technology.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization of its therapeutic candidates. Analyst estimates are not readily available for smaller, development-stage companies.
Recent Initiatives: Recent initiatives include advancing its clinical programs, securing funding, and exploring potential partnerships.
Summary
Serina Therapeutics is a development-stage company with a promising POZ Platform technology. Its success hinges on advancing its clinical programs and securing regulatory approvals. The company faces significant competition and financial challenges, but its innovative technology offers potential for growth. Early indications are promising, yet the company needs to mitigate risk to stay afloat and become more profitable.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Press releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data and analysis are based on publicly available information and are subject to change. Investing in development-stage companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Serina Therapeutics Inc
Exchange NYSE MKT | Headquaters Huntsville, AL, United States | ||
IPO Launch date 2018-11-29 | CEO & Director Mr. Steven A. Ledger | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://serinatherapeutics.com |
Full time employees 12 | Website https://serinatherapeutics.com | ||
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.